We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Neon Healthcare Ltd is recalling the specific batch mentioned in this notification as a precautionary measure.
You must get permission to export certain drugs and medicines.
Novartis Pharmaceuticals UK Limited is recalling Adakveo 10 mg/ml concentrate for solution for infusion due to the benefit-risk balance of Adakveo no longer being considered favourable by the MHRA.
Pharmacy, prescription-only (POM), and general sale list (GSL) medicines: apply to move your medicine to a different classification.
Fresenius Kabi Limited has informed the MHRA of an error on the infusion bag packaged into the specific batches of Sodium Chloride Intravenous Infusion 0.9% Freeflex.
Guidance on how to license electronic cigarettes and other inhaled nicotine-containing products (NCPs) as medicines in the UK.
Bristol-Myers Squibb Pharmaceuticals Limited has informed the MHRA that a potential product quality issue has been detected, relating to incomplete crimping of the metal crimp cap of OPDIVO 10mg/mL concentrate for solution for infusion (nivolumab) (1VLX10ML).
A new pathway supporting innovative approaches to the safe, timely and efficient development of medicines to improve patient access.
medac GmbH (t/a medac Pharma LLP) is recalling the product for the batch specified in this notification due to particles detected during long-term stability tests.
Information for patients, healthcare professionals and developers of new medicines
What you need to do to supply authorised medicines from Great Britain to Northern Ireland.
Industry must notify the MHRA if they will not be using these flexibilities
Safety leaflet on opioid medicines to help patients and their families reduce the risks of harm.
MV Chinfield antifatigue bronchospasmolytic for thoroughbreds seized at a Belfast courier company.
Information and documents on Public Health England’s review of the evidence for dependence on, and withdrawal from, prescribed medicines.
Guidance on applications and licences for manufacturers & wholesalers, suspended and revoked licences, registrations, exporting medicines, defective medicinal products and fees.
The MHRA has reviewed the latest evidence relating to the very rare risk of PRES and RCVS associated with medicines containing pseudoephedrine
How to prepare for implementation and compliance of the Safety Features Regulation.
How the MHRA makes decisions on what is a medicinal product (borderline products).
The company has informed us that the consistency of the product within the batches has a reduced viscosity and more closely resembles a lotion than a cream.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.